E-LIB Suche - Ergebnisse für: Boyiadzis, M.

1

P563: A RANDOMIZED, DOUBLE-BLIND, 2-ARM, MULTICENTER, PH3 S..:

Ivanov, V. ; Yeh, S.-P. ; Mayer, J....
HemaSphere. 6 (2022) - p. 462-463 , 2022

Link: https://doi.org/10.1097/..

2

The emerging roles of tumor-derived exosomes in hematologic..:

Boyiadzis, M ; Whiteside, T L
Leukemia. 31 (2017) 6 - p. 1259-1268 , 2017

Link: https://doi.org/10.1038/..

3

Response commentary: exosomes vs microvesicles in hematolog..:

Whiteside, T L ; Boyiadzis, M
Leukemia. 31 (2017) 10 - p. 2277-2277 , 2017

Link: https://doi.org/10.1038/..

4

Natural killer cell (NK) subsets and NK-like T-cell populat..:

Aggarwal, N. ; Swerdlow, S. H. ; TenEyck, S. P...
Cytometry Part B: Clinical Cytometry. 90 (2016) 4 - p. 349-357 , 2016

Link: https://doi.org/10.1002/..

5

Impact of Chronic GVHD on Late Relapse, Treatment Related M..:

Boyiadzis, M. ; Klein, J.P. ; Arora, M....
Biology of Blood and Marrow Transplantation. 18 (2012) 2 - p. S209-S210 , 2012

Link: https://doi.org/10.1016/..

6

IL-15 as a potential regulator of peripheral NK and CD8+ T ..:

Carson, J.M. ; Villalba, H. ; Boyiadzis, M....
Biology of Blood and Marrow Transplantation. 10 (2004) - p. 59 , 2004

Link: https://doi.org/10.1016/..

7

Pevonedistat with azacitidine in older patients with TP53-m..:

Saliba, Antoine N. ; Kaufmann, Scott H. ; Stein, Eytan M....
Blood Advances. 7 (2023) 11 - p. 2360-2363 , 2023

Link: https://doi.org/10.1182/..

8

Rates and Predictors of Nonadherence to the Post-Allogeneic..:

Posluszny, Donna M. ; Bovbjerg, Dana H. ; Syrjala, Karen L....
Transplantation and Cellular Therapy. 28 (2022) 3 - p. 165.e1-165.e9 , 2022

Link: https://doi.org/10.1016/..

9

The Society for Immunotherapy of Cancer (SITC) clinical pra..:

Boyiadzis, Michael M ; Aksentijevich, Ivan ; Arber, Daniel A...
Journal for ImmunoTherapy of Cancer. 8 (2020) 2 - p. e000810 , 2020

Link: https://doi.org/10.1136/..

10

Chimeric antigen receptor (CAR) T therapies for the treatme..:

Boyiadzis, Michael M. ; Dhodapkar, Madhav V. ; Brentjens, Renier J....
Journal for ImmunoTherapy of Cancer. 6 (2018) 1 - p. , 2018

Link: https://doi.org/10.1186/..

11

Significance and implications of FDA approval of pembrolizu..:

Boyiadzis, Michael M. ; Kirkwood, John M. ; Marshall, John L....
Journal for ImmunoTherapy of Cancer. 6 (2018) 1 - p. , 2018

Link: https://doi.org/10.1186/..

12

Patient and family caregiver dyadic adherence to the alloge..:

Posluszny, Donna M. ; Bovbjerg, Dana H. ; Agha, Mounzer E....
Psycho-Oncology. 27 (2017) 1 - p. 354-358 , 2017

Link: https://doi.org/10.1002/..

13

Book Review: Hematology–Oncology Therapy:

Boyiadzis, Michael M ; Lebowitz, Peter F ; Frame, James N..
Annals of Pharmacotherapy. 41 (2007) 2 - p. 361-361 , 2007

Link: https://doi.org/10.1345/..

14

Pevonedistat with azacitidine in older patients with TP53-m..:

Saliba, Antoine N ; Kaufmann, Scott H ; Stein, Eytan M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230164/. , 2022

Link: http://www.ncbi.nlm.nih...

15

Rates and Predictors of Nonadherence to the Post Allogeneic..:

Posluszny, Donna M ; Bovbjerg, Dana H ; Syrjala, Karen L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004486/. , 2022

Link: http://www.ncbi.nlm.nih...